John W. Day, MD, PhD, Professor of
Neurology and Pediatrics, and Director, Division of Neuromuscular
Medicine, Stanford University School of
Medicine and a principal investigator in END-DM1, ongoing natural
history study will join Avidity management to present data
from MARINA-OLE™
Avidity to host Volume 8 of investor and
analyst event series via webcast March 4,
2024, at 8:00 a.m. ET
SAN
DIEGO, Feb. 15, 2024 /PRNewswire/ -- Avidity
Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company
committed to delivering a new class of RNA therapeutics called
Antibody Oligonucleotide Conjugates (AOCs™), today announced that
the company will be presenting multiple posters from all three
clinical development programs in rare muscle diseases, including
new AOC 1001 long-term efficacy and safety data from the MARINA
open-label extension (MARINA-OLE™) trial in people living with
myotonic dystrophy type 1 (DM1) at the 2024 Muscular Dystrophy
Association (MDA) Clinical & Scientific Conference being held
March 3-6, 2024, in Orlando, Florida.
In addition, Avidity management will be joined by John W.
Day, MD, PhD, Professor of Neurology and Pediatrics, and
Director, Division of Neuromuscular Medicine, Stanford University School of Medicine on
March 4, 2024, at 8:00 a.m. ET for a live video webcast event,
which will be available on the company's website.
Dr. Day is one of the principal investigators in END-DM1, an
ongoing natural history study being run by the Myotonic Dystrophy
Clinical Research Network (DMCRN) and is an investigator in the AOC
1001 Phase 1/2 MARINA® trial and the MARINA-OLE
trial.
POSTER PRESENTATIONS
March 4, 2024: 6:00 p.m. – 8:00 p.m.
ET
- AOC 1044 as a Novel Therapeutic Approach for DMD Patients
Amenable to Exon 44 Skipping: EXPLORE44 Phase 1/2 Healthy Volunteer
Data
March 5, 2024: 6:00 p.m. – 8:00 p.m.
ET
- Initial results of the Phase 2 Open-Label Extension Study of
AOC 1001 in Adults with Myotonic Dystrophy Type 1:
MARINA-OLE™
- AOC 1001-mediated Reduction of DMPK Leads to Increase in
Functional MBNL Levels, Improving Muscle Function in Patients with
DM1
- Targeting DUX4 for Silencing with AOC for the Treatment of
FSHD
- Increasing Diversity in Clinical Trial Participation: An
Exploration of Clinical Trial Site Engagement
All posters will be viewable on the MDA Clinical &
Scientific Conference virtual platform March
3-5, 2024, 6:00 p.m. – 8:00 p.m.
ET and will also be available on the publications
page of Avidity's website at
https://www.aviditybiosciences.com.
Video Webcast Information
The company is hosting
Volume 8 of its investor and analyst event series on March 4, 2024, beginning at 8:00 a.m. ET to discuss new AOC 1001 long-term
efficacy and safety data from the MARINA-OLE™ trial in people
living with DM1. The virtual event will be available via a live
video webcast and can be accessed here or from the "Events and
Presentations" page in the "Investors" section of Avidity's
website. A replay of the webcast will be archived on Avidity's
website following the event.
About Avidity
Avidity Biosciences, Inc.'s mission is
to profoundly improve people's lives by delivering a new class of
RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™).
Avidity is revolutionizing the field of RNA with its proprietary
AOCs, which are designed to combine the specificity of monoclonal
antibodies with the precision of oligonucleotide therapies to
address targets and diseases previously unreachable with existing
RNA therapies. Utilizing its proprietary AOC platform, Avidity
demonstrated the first-ever successful targeted delivery of RNA
into muscle and is leading the field with clinical development
programs for three rare muscle diseases: myotonic dystrophy type 1
(DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral
muscular dystrophy (FSHD). Avidity is broadening the reach of AOCs
with its advancing and expanding pipeline including programs in
cardiology and immunology through internal discovery efforts and
key partnerships. Avidity is headquartered in San Diego, CA. For more information about our
AOC platform, clinical development pipeline and people, please
visit www.aviditybiosciences.com and engage with us on LinkedIn and
X.
Forward-Looking Statements
Avidity cautions readers
that statements contained in this press release regarding matters
that are not historical facts are forward-looking statements. These
statements are based on the company's current beliefs and
expectations. Such forward-looking statements include, but are not
limited to, statements regarding the topics of poster presentations
Avidity plans to present at the 2024 MDA Clinical and Scientific
Conference, including long-term efficacy and safety data from
the MARINA-OLE™ trial. The inclusion of forward-looking
statements should not be regarded as a representation by Avidity
that any of these plans will be achieved. Actual results may differ
from those set forth in this press release due to the risks and
uncertainties inherent in Avidity's business and beyond its
control, including risks described in Avidity's Annual Report on
Form 10-K for the fiscal year ended December
31, 2022, and in subsequent SEC filings and press releases.
Avidity cautions readers not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and the company undertakes no obligation to update such statements
to reflect events that occur or circumstances that arise after the
date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, which is made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995.
Investor Contact:
Geoffrey
Grande, CFA
(619) 837-5014
investors@aviditybio.com
Media Contact:
Navjot
Rai
(619) 837-5016
media@aviditybio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/avidity-biosciences-to-present-new-aoc-1001-long-term-efficacy-and-safety-data-from-marina-ole-trial-in-people-living-with-myotonic-dystrophy-type-1-dm1-at-2024-muscular-dystrophy-association-mda-clinical--scientific-confere-302063559.html
SOURCE Avidity Biosciences, Inc.